Dilution profile // every instrument, one screen, from SEC filings

DiaMedica Therapeutics Inc. (DMAC)

CIK 1401040 · all EDGAR filings →

Overall dilution risk
HIGHworst of 3 computed signals (offering ability)
= the worst band among the computed sub-ratings, no hidden weighting
not every sub-rating was computable; treat as a floor
Offering ability
HIGH$139M registered
= total registered offering amount from the fee exhibits of live registrations (bands: $1M / $20M)
one or more live registrations had no structured fee data, so the true total is AT LEAST this
Overhead supply
NOT COMPUTEDno warrant count tagged in XBRL
= warrant shares outstanding divided by current shares outstanding
absence of a tag is not proof of absence of warrants
Historical dilution
MEDIUM+42% O/S in 3y
= share count now vs 3 years ago (bands: 30% / 100%); a reverse split pushes this negative
Cash need
MEDIUM~18 months of runway
= cash vs trailing operating burn (bands: 6mo / 24mo; positive operating CF = low)

Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.

Shares outstanding over time

2020-11-022026-08-03

Latest: 53.9M shares as of Aug 3, 2026 (10-Q).

Cash runway

Funded — but tight

~18 months of cash · watch

Full breakdown: cash runway tool · source filing →

Warrants

Balance-sheet fair value of warrants: $84,000 as of Dec 31, 2017.

Convertible notes

No convertible-note facts tagged in the 10-Q filed Aug 10, 2026. If convertible notes exist, their terms live in exhibit prose for this filer and are not parsed; absence of a tag is not proof of absence. The exhibits are the ground truth.

Registrations and offerings

Registered offering capacity on live registrations: $139.2Mfrom the structured fee exhibits; registered is not remaining, takedowns are not subtracted

S-3Aug 12, 2025$100.0M registeredfiling →
S-3Aug 1, 2025$39.2M registeredfiling →
S-3Jul 10, 2024no structured fee exhibit in this filing (predates fee-data XBRL or fee deferred)filing →

Last 12 months: 1 executed · 0 registered.

EXECUTEDAug 22, 2025Prospectus supplement priced — shares or notes (large filers: often a bond deal)424B2
EFFECTIVEAug 22, 2025SEC declared a registration effective — selling can beginEFFECT
REGISTEREDAug 12, 2025S-3 registration — capacity to sell shares, not a sale yetS-3
EFFECTIVEAug 8, 2025SEC declared a registration effective — selling can beginEFFECT
REGISTEREDAug 1, 2025S-3 registration — capacity to sell shares, not a sale yetS-3
EXECUTEDJul 21, 2025Unregistered share sale disclosed (8-K item 3.02)8-K
UPDATEJul 18, 2024Prospectus update — often a resale registration, not necessarily new capital424B3
EFFECTIVEJul 18, 2024SEC declared a registration effective — selling can beginEFFECT
REGISTEREDJul 10, 2024S-3 registration — capacity to sell shares, not a sale yetS-3
EXECUTEDJun 26, 2024Unregistered share sale disclosed (8-K item 3.02)8-K
EFFECTIVEApr 9, 2024SEC declared a registration effective — selling can beginEFFECT
REGISTEREDMar 21, 2024S-3 registration — capacity to sell shares, not a sale yetS-3

Full history and shelf status: offering checker · S-3 shelf checker

Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.

Keep going: float checker · offering calendar · short-squeeze screener · full DMAC workspace